72 related articles for article (PubMed ID: 29704589)
1. Mitochondrial alterations in Parkinson's disease human samples and cellular models.
Zilocchi M; Finzi G; Lualdi M; Sessa F; Fasano M; Alberio T
Neurochem Int; 2018 Sep; 118():61-72. PubMed ID: 29704589
[TBL] [Abstract][Full Text] [Related]
2. Dopamine‑iron homeostasis interaction rescues mitochondrial fitness in Parkinson's disease.
Buoso C; Seifert M; Lang M; Griffith CM; Talavera Andújar B; Castelo Rueda MP; Fischer C; Doerrier C; Talasz H; Zanon A; Pramstaller PP; Schymanski EL; Pichler I; Weiss G
Neurobiol Dis; 2024 Jun; 196():106506. PubMed ID: 38648865
[TBL] [Abstract][Full Text] [Related]
3. Pathological mechanisms and treatment of sporadic Parkinson's disease: past, present, and future.
Mochizuki H
J Neural Transm (Vienna); 2024 Jun; 131(6):597-607. PubMed ID: 38864935
[TBL] [Abstract][Full Text] [Related]
4. Mitochondrial complex I deficiency stratifies idiopathic Parkinson's disease.
Flønes IH; Toker L; Sandnes DA; Castelli M; Mostafavi S; Lura N; Shadad O; Fernandez-Vizarra E; Painous C; Pérez-Soriano A; Compta Y; Molina-Porcel L; Alves G; Tysnes OB; Dölle C; Nido GS; Tzoulis C
Nat Commun; 2024 Apr; 15(1):3631. PubMed ID: 38684731
[TBL] [Abstract][Full Text] [Related]
5. Enteric neurons from Parkinson's disease patients display ex vivo aberrations in mitochondrial structure.
Baumuratov AS; Antony PM; Ostaszewski M; He F; Salamanca L; Antunes L; Weber J; Longhino L; Derkinderen P; Koopman WJ; Diederich NJ
Sci Rep; 2016 Sep; 6():33117. PubMed ID: 27624977
[TBL] [Abstract][Full Text] [Related]
6. Orthogonal analysis of mitochondrial function in Parkinson's disease patients.
Barnhoorn S; Milanese C; Li T; Dons L; Ghazvini M; Sette M; Farina S; Sproviero D; Payan-Gomez C; Mastroberardino PG
Cell Death Dis; 2024 Apr; 15(4):243. PubMed ID: 38570521
[TBL] [Abstract][Full Text] [Related]
7. A small molecule 20C from Gastrodia elata inhibits α-synuclein aggregation and prevents progression of Parkinson's disease.
Peng Y; Ye JR; Wang SS; He WB; Feng ZP; Sun HS; Chu SF; Zhang Z; Chen NH
Cell Death Dis; 2023 Sep; 14(9):594. PubMed ID: 37673867
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic Potential of Heterocyclic Compounds Targeting Mitochondrial Calcium Homeostasis and Signaling in Alzheimer's Disease and Parkinson's Disease.
Tapias V; González-Andrés P; Peña LF; Barbero A; Núñez L; Villalobos C
Antioxidants (Basel); 2023 Jun; 12(6):. PubMed ID: 37372013
[TBL] [Abstract][Full Text] [Related]
9. The case for FAT10 as a novel target in fatty liver diseases.
Wimalarathne MM; Wilkerson-Vidal QC; Hunt EC; Love-Rutledge ST
Front Pharmacol; 2022; 13():972320. PubMed ID: 36386217
[TBL] [Abstract][Full Text] [Related]
10. Defective PTEN-induced kinase 1/Parkin mediated mitophagy and neurodegenerative diseases.
Braun MM; Puglielli L
Front Cell Neurosci; 2022; 16():1031153. PubMed ID: 36339819
[TBL] [Abstract][Full Text] [Related]
11. Adult health and transition stage-specific rotenone-mediated
Ayajuddin M; Phom L; Koza Z; Modi P; Das A; Chaurasia R; Thepa A; Jamir N; Neikha K; Yenisetti SC
Front Mol Neurosci; 2022; 15():896183. PubMed ID: 36017079
[TBL] [Abstract][Full Text] [Related]
12. Mitochondrial behavior when things go wrong in the axon.
Pozo Devoto VM; Onyango IG; Stokin GB
Front Cell Neurosci; 2022; 16():959598. PubMed ID: 35990893
[TBL] [Abstract][Full Text] [Related]
13. 4-Phenylbutyrate Mitigates the Motor Impairment and Dopaminergic Neuronal Death During Parkinson's Disease Pathology via Targeting VDAC1 Mediated Mitochondrial Function and Astrocytes Activation.
Tiwari S; Gupta P; Singh A; Chaturvedi S; Wahajuddin M; Mishra A; Singh S
Neurochem Res; 2022 Nov; 47(11):3385-3401. PubMed ID: 35922743
[TBL] [Abstract][Full Text] [Related]
14. Hallmarks and Molecular Tools for the Study of Mitophagy in Parkinson's Disease.
Goiran T; Eldeeb MA; Zorca CE; Fon EA
Cells; 2022 Jul; 11(13):. PubMed ID: 35805181
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of miR-421 Preserves Mitochondrial Function and Protects against Parkinson's Disease Pathogenesis via Pink1/Parkin-Dependent Mitophagy.
Dong X; He X; Yang L; Li Q; Xu Y
Dis Markers; 2022; 2022():5186252. PubMed ID: 35664430
[TBL] [Abstract][Full Text] [Related]
16. Contribution of Mitochondrial Dysfunction Combined with NLRP3 Inflammasome Activation in Selected Neurodegenerative Diseases.
Litwiniuk A; Baranowska-Bik A; Domańska A; Kalisz M; Bik W
Pharmaceuticals (Basel); 2021 Nov; 14(12):. PubMed ID: 34959622
[TBL] [Abstract][Full Text] [Related]
17. Insights into the Pathogenesis of Neurodegenerative Diseases: Focus on Mitochondrial Dysfunction and Oxidative Stress.
Jurcau A
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769277
[TBL] [Abstract][Full Text] [Related]
18. Disease-modifying treatment of Parkinson's disease by phytochemicals: targeting multiple pathogenic factors.
Naoi M; Maruyama W; Shamoto-Nagai M
J Neural Transm (Vienna); 2022 Jun; 129(5-6):737-753. PubMed ID: 34654977
[TBL] [Abstract][Full Text] [Related]
19. Alpha-Synuclein as a Biomarker of Parkinson's Disease: Good, but Not Good Enough.
Ganguly U; Singh S; Pal S; Prasad S; Agrawal BK; Saini RV; Chakrabarti S
Front Aging Neurosci; 2021; 13():702639. PubMed ID: 34305577
[TBL] [Abstract][Full Text] [Related]
20. Selective Neuron Vulnerability in Common and Rare Diseases-Mitochondria in the Focus.
Paß T; Wiesner RJ; Pla-Martín D
Front Mol Biosci; 2021; 8():676187. PubMed ID: 34295920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
